ANVS

MKT CAP:$35M

Annovis Bio, Inc.

Market Cap

$35M

Healthcare·Biotechnology·🇺🇸 United States·NYSE

Healthcare·Biotechnology·🇺🇸·NYSE

Stock Price

$1.80-$1.84 (-50.55%)

Apr 23, 2026

Company Details

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of ...

CEO

Maria L. Maccecchini

IPO Date

Jan 29, 2020

Website

www.annovisbio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$25M

EPS (Diluted)

-$1.62

Free Cash Flow

-$25M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q3 2025

Nov 12, 2025

$0EPS -$0.37

Q2 2025

Aug 12, 2025

$0EPS -$0.32

Q1 2025

May 13, 2025

$0EPS -$0.45

Q4 2024

Mar 21, 2025

$0EPS -$0.48

Q3 2024

Nov 8, 2024

$0EPS -$0.97

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 21	$0	$0	-$3M
Q4 21	$0	$0	-$6M
Q1 22	$0	$0	$5M
Q2 22	$0	$0	-$6M
Q3 22	$0	$0	-$6M
Q1 23	$0	$0	-$10M
Q2 23	$0	$0	-$10M
Q3 23	$0	$0	-$15M
Q4 23	$0	$0	-$10M
Q1 24	$0	$0	-$8M
Q2 24	$0	$0	-$8M
Q3 24	$0	$0	-$4M
Q4 24	$0	$0	-$7M
Q1 25	$0	$0	-$6M
Q2 25	$0	$0	-$6M
Q3 25	$0	$0	-$7M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 21	-$2M	-$2M
Q4 21	-$2M	-$2M
Q1 22	-$3M	-$3M
Q2 22	-$7M	-$7M
Q3 22	-$4M	-$4M
Q1 23	-$12M	-$12M
Q2 23	-$10M	-$10M
Q3 23	-$9M	-$9M
Q4 23	-$9M	-$9M
Q1 24	-$7M	-$7M
Q2 24	-$3M	-$3M
Q3 24	-$3M	-$3M
Q4 24	-$8M	-$8M
Q1 25	-$8M	-$8M
Q2 25	-$5M	-$5M
Q3 25	-$3M	-$3M

Capital Expenditures

Quarter	CapEx
Q3 21	$2
Q4 21	$0
Q1 22	$1
Q2 22	$3
Q3 22	$0
Q1 23	$3
Q2 23	$0
Q3 23	$3
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$5

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 21	—	+77.9%
Q4 21	—	+210.0%
Q1 22	—	-262.7%
Q2 22	—	+135.7%
Q3 22	—	+127.2%
Q1 23	—	+68.4%
Q2 23	—	+285.8%
Q3 23	—	+148.9%
Q4 23	—	+61.0%
Q1 24	—	-21.7%
Q2 24	—	-20.5%
Q3 24	—	-70.5%
Q4 24	—	-35.5%
Q1 25	—	-19.6%
Q2 25	—	-19.2%
Q3 25	—	+69.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 21	$785.9K	—
Q4 21	$4M	—
Q1 22	$3M	—
Q2 22	$2M	—
Q3 22	$2M	—
Q1 23	$2M	—
Q2 23	$2M	—
Q3 23	$632.2K	—
Q4 23	$882.4K	—
Q1 24	$364.8K	—
Q2 24	$2M	—
Q3 24	$393.1K	—
Q4 24	$1M	—
Q1 25	$499.9K	—
Q2 25	$496.6K	—
Q3 25	$444.6K	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q3 21	$1M	$1M	—	—
Q4 21	$3M	$3M	—	—
Q1 22	$2M	$3M	—	—
Q2 22	$4M	$2M	—	—
Q3 22	$4M	$2M	—	—
Q1 23	$8M	$2M	—	—
Q2 23	$8M	$1M	—	—
Q3 23	$14M	$1M	—	—
Q4 23	$9M	—	—	$2M
Q1 24	$7M	$1M	—	—
Q2 24	$6M	$2M	—	—
Q3 24	$3M	$2M	—	—
Q4 24	$5M	$2M	$100.0K	—
Q1 25	$5M	$1M	—	—
Q2 25	$5M	$1M	—	—
Q3 25	$6M	—	—	$1M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$43M	$0	$43M
Q2 22	$36M	$0	$36M
Q3 22	$32M	$0	$32M
Q4 22	$28M	$0	$28M
Q1 23	$17M	$0	$17M
Q2 23	$16M	$0	$16M
Q3 23	$6M	$0	$6M
Q4 23	$6M	$0	$6M
Q1 24	$3M	$0	$3M
Q2 24	$4M	$0	$4M
Q3 24	$13M	$0	$13M
Q4 24	$11M	$0	$11M
Q1 25	$22M	$0	$22M
Q2 25	$17M	$0	$17M
Q3 25	$15M	$0	$15M
Q4 25	$19.5B	$0	$19.5B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 21	8M	+9.9%	+17.9%
Q4 21	8M	0.0%	+17.0%
Q1 22	8M	+0.7%	+17.9%
Q2 22	8M	+0.1%	+10.8%
Q3 22	8M	0.0%	+0.8%
Q1 23	8M	+0.4%	+1.2%
Q2 23	9M	+9.2%	+9.7%
Q3 23	9M	+0.7%	+10.4%
Q4 23	10M	+5.7%	+16.7%
Q1 24	11M	+11.5%	+29.7%
Q2 24	11M	+6.4%	+26.3%
Q3 24	13M	+14.8%	+44.0%
Q4 24	14M	+6.3%	+44.8%
Q1 25	12M	-11.3%	+15.2%
Q2 25	19M	+59.3%	+72.3%
Q3 25	20M	+1.0%	+51.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 21	$0	2
Q4 21	$0	4
Q1 22	$0	4
Q2 22	$0	4
Q3 22	$0	4
Q1 23	$0	5
Q2 23	$0	5
Q3 23	$0	5
Q4 23	$0	6
Q1 24	$0	6
Q2 24	$0	6
Q3 24	$0	6
Q4 24	$0	8
Q1 25	$0	8
Q2 25	$0	8
Q3 25	$0	8

Revenue / Employee